The major histocompatibility complex class I (MHC-I) antigen presentation pathway is central to the adaptive immune response. In this process, intracellular proteins are degraded primarily by the ...
Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
The in situ formed hydrogel vaccine creates an immune niche to coordinate the spatiotemporal dynamics of vaccine components and dendritic cells, eliciting durable and enhanced immunity against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results